Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Bahram Valamehr M.B.A., Ph.D. | President & CEO | 644.5k | -- | 1978 |
| Ms. Cindy R. Tahl J.D. | Chief Legal & Compliance Officer and Corporate Secretary | 612.5k | -- | 1973 |
| Mr. Victor Hong | Vice President of Corporate Development & Finance | -- | -- | -- |
| Ms. Jessica Francis | Vice President Of Human Resources & Operations | -- | -- | -- |
| Mr. Andrew Henry | Senior Vice President of Clinical Operations | -- | -- | 1964 |
| Dr. Tunde Babalola | Senior Vice President of Technical Operations | -- | -- | -- |
| Dr. Yu Cai | Head of Intellectual Property & Assistant General Counsel | -- | -- | -- |
Fate Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 181
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
May 7, 2025 at 8:00 PM UTC - May 12, 2025 at 8:00 PM UTC
Fate Therapeutics, Inc. Earnings Date